Infinity Initiates Phase 2 Trial of IPI-926 in Patients With Chondrosarcoma
03 mars 2011 08h00 HE
|
Infinity Pharmaceuticals, Inc.
— Company Granted U.S. Orphan Drug Designation for IPI-926 for the Treatment of Chondrosarcoma —
— Rationale for Developing IPI-926 in Chondrosarcoma to be...
Infinity Pharmaceuticals to Present at Two Upcoming Conferences
28 févr. 2011 08h00 HE
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Feb. 28, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) will be presenting at the Cowen and Company 31st Annual Health Care Conference on Monday, March 7, 2011...
Infinity Initiates Phase 2 Portion of Trial of IPI-926 in Pancreatic Cancer
22 févr. 2011 08h00 HE
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Feb. 22, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today announced the initiation of the randomized Phase 2 portion of the trial of IPI-926 in combination...
Infinity Provides 2011 Goals and Guidance
07 janv. 2011 08h01 HE
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Jan. 7, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) today provided guidance on its anticipated pipeline and business goals for 2011. Infinity begins the...
Infinity Pharmaceuticals to Present at 29th Annual J.P. Morgan Healthcare Conference
05 janv. 2011 08h30 HE
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Jan. 5, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) will be presenting at the J.P. Morgan 29th Annual Healthcare Conference on Thursday, January 13, 2011 at...
Infinity Elevated to NASDAQ Global Select Market
03 janv. 2011 08h00 HE
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Jan. 3, 2011 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) announces that, effective today, it has been named to the NASDAQ Global Select Market tier, the premier...
Infinity and Mundipharma Extend Global Strategic Alliance
13 déc. 2010 06h30 HE
|
Infinity Pharmaceuticals, Inc.
Mundipharma Commits to Providing Up to $110 Million in R&D Funding for 2012 in Addition to $85 Million Previously Committed for 2011
Companies Agree Upon Event-Based Approach for IPI-926...
Infinity Pharmaceuticals to Present at Piper Jaffray Healthcare Conference
22 nov. 2010 08h00 HE
|
Infinity Pharmaceuticals, Inc.
CAMBRIDGE, Mass., Nov. 22, 2010 (GLOBE NEWSWIRE) -- Infinity Pharmaceuticals, Inc. (Nasdaq:INFI) will be presenting at the Piper Jaffray 22nd Annual "Unplugged" Health Care Conference on Wednesday,...
Infinity Conducting Clinical Trial in Patients With Pancreatic Cancer in Denver
16 nov. 2010 10h02 HE
|
Infinity Pharmaceuticals, Inc.
Ongoing Clinical Trial Evaluating a New Approach for Pancreatic Cancer, One of the Most Difficult to Treat Cancers
Spotlight on Pancreatic Cancer Awareness Month in November
DENVER, Nov. 16,...
Infinity Conducting Clinical Trial in Patients With Pancreatic Cancer in Boston
16 nov. 2010 08h00 HE
|
Infinity Pharmaceuticals, Inc.
– Ongoing Clinical Trial Evaluating a New Approach for Pancreatic Cancer,
One of the Most Difficult to Treat Cancers –
– Spotlight on Pancreatic...